2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-103340
    O-2093 439080-01-0 98%
    O-2093 is a selective endocannabinoid anandamide (AEA) reuptake inhibitor with IC50 of 17.3 μM.
    O-2093
  • HY-103341
    UCM707 390824-20-1 98%
    UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of Anandamide.
    UCM707
  • HY-103342
    OMDM-2 616884-63-0 98%
    OMDM-2 is a potent, selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a Ki of 3.0 μM.
    OMDM-2
  • HY-103357
    LY288513 147523-65-7 98%
    LY288513 is a selective non-peptide CCK-B receptor antagonist with an IC50 value of 16 nM. LY288513 produces an anxiolytic-like action in mice.
    LY288513
  • HY-103378
    NBI 35965 methanesulfonate 603151-83-3 98%
    NBI 35965 methanesulfonate is a selective, orally active and brain-penetrant corticotropin-releasing factor receptor 1 (CRF1) antagonist with a Ki value of 4 nM and a pKi value of 8.5. NBI 35965 methanesulfonate does not inhibit CRF2. NBI 35965 methanesulfonate reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC50 values of 7.1 and 6.9, respectively. NBI 35965 methanesulfonate shows anxiolytic effects.
    NBI 35965 methanesulfonate
  • HY-103379
    CP 376395 hydrochloride 1013933-37-3 98%
    CP 376395 hydrochloride is a potent, selective, and brain-penetrable Corticotropin releasing factor 1 (CRF1) receptor antagonist.
    CP 376395 hydrochloride
  • HY-103403
    (-)-OSU6162 hydrochloride 156907-84-5 98%
    (-)-OSU6162 (PNU96391) hydrochloride is a dopamine stabilizer. (-)-OSU6162 hydrochloride acts as partial agonist at 5-HT2A and is a dopamine D2 antagonist. (-)-OSU6162 hydrochloride can be used for the research of aggression and irritability.
    (-)-OSU6162 hydrochloride
  • HY-103404
    PNU-96415E 170856-41-4 98%
    PNU-96415E is a selective D4/5-HT2A antagonist. PNU-96415E may have potential antipsychotic efficacy.
    PNU-96415E
  • HY-103406
    PNU-177864 250266-51-4 98%
    PNU-177864 is a potent, selective, orally active dopamine D3 receptor antagonist. PNU-177864 induces phospholipid metabolism in vivo and has anti-schizophrenia activity.
    PNU-177864
  • HY-103407
    PD 168568 210688-56-5 98%
    PD 168568 is a orally active and potent dopamine receptor D4 (DRD4) antagonist. PD 168568 contains an isoindolinone and is selective for the D4 receptor versus D2 and D3, with Ki values of 8.8, 1842, and 2682 nM, respectively. PD 168568 can be used for glioblastoma (GBM) research.
    PD 168568
  • HY-103411
    SKF83822 hydrobromide 74115-10-9 98%
    SKF83822 hydrobromide is a potent dopamine D1 receptor agonist. SKF83822 hydrobromide activates Gs/olf/adenylyl cyclase (AC)-coupled D1 receptors, but not phospholipase C (PLC)-coupled D1-like receptors.
    SKF83822 hydrobromide
  • HY-103418
    Dopamine D2 receptor agonist-3 1257326-24-1 98.30%
    Dopamine D2 receptor agonist-3 (compound 3) is a selective D2 receptor partial agonist and Dopamine D3 receptor antagonist (with pEC50 of 8.3 and <5.5 respectively).
    Dopamine D2 receptor agonist-3
  • HY-103424
    A-412997 dihydrochloride 1347744-96-0 98%
    A-412997 dihydrochloride is a selective dopamine D4 receptor agonist. A-412997 dihydrochloride improves cognitive performance in rats and can be used in the research of psychiatric diseases.
    A-412997 dihydrochloride
  • HY-103425
    JHW007 hydrochloride 202645-74-7 98%
    JHW007 hydrochloride is the hydrochloride of JHW007. JHW007 is an antagonist of cocaine.
    JHW007 hydrochloride
  • HY-103427
    NPEC-caged-dopamine 1257326-23-0 99.94%
    NPEC-caged-dopamine is a caged version of dopamine. NPEC-caged-Dopamine was used by applying focal photolysis with UV light (360 nm) to releases dopamine, which leads to D1 receptor activation.
    NPEC-caged-dopamine
  • HY-103463
    SA57 1346169-63-8 ≥99.0%
    SA57 is a potent, selective FAAH inhibitor with IC50s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC50s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC50 of 850 nM), but not other brain serine hydrolases.
    SA57
  • HY-103495
    17-PA 694438-95-4 98%
    17-PA is a selective antagonist of neurosteroid potentiation and direct gating of GABAA receptors.
    17-PA
  • HY-103497
    U-89843A hydrochloride 157013-85-9 98%
    U-89843A is an allosteric modulator of GABAA receptor. U-89843A enhances GABA-induced Cl- currents.
    U-89843A hydrochloride
  • HY-103498
    Org20599 156685-94-8 98%
    Org20599 is a positive allosteric modulator and at higher concentrations direct agonist of GABAA receptor with an EC50 of 1.1 μM.
    Org20599
  • HY-103499
    ZK 93426 hydrochloride 1216792-30-1 98%
    ZK 93426 (hydrochloride) is a benzodiazepine antagonist. ZK 93426 (hydrochloride) can be used for the research of neurological disease.
    ZK 93426 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity